Method for producing biopharmacy raw material, system for producing biopharmacy raw material, and biopharmacy raw material

By using one-way tangential flow filtration and optimized design of sterile filters in the continuous production system of biopharmaceuticals, the frequent failure of chromatographic devices is solved, the system maintainability and production stability are improved, and the biopharmaceuticals is ensured. Quality and productivity.

CN118973592APending Publication Date: 2024-11-15FUJIFILM CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030755.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-30
Filing Date
2023-03-30
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

During the continuous production of biopharmaceuticals, frequent failures of chromatography devices lead to a decrease in maintainability, affecting production efficiency and product quality.

Method used

Purification filter adopts a one-way tangential flow filtration method, and a sterile filter with a larger pore size than the cell filter is installed on the connecting pipeline, and a sterile filter with a flat filter paper folding structure and a hollow fiber bundling structure are optimized. Filtration area and flow management to reduce load and failure risk of sterile filters.

Benefits of technology

It effectively suppresses the frequency of chromatographic device failures, improves the system's maintainability and continuous production stability, extends the service life of sterile filters, and ensures the quality and productivity of biopharmaceuticals.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118973592A_ABST
    Figure CN118973592A_ABST
Patent Text Reader

Abstract

A method for producing a bulk drug for biopharmacy, in which a culture unit for performing a culture process for culturing cells in a culture solution stored in a culture tank and a purification unit for purifying the cells are connected by means of a connection line, and a purification unit that performs a purification process for obtaining a biopharmaceutical bulk drug by purifying the product from the culture supernatant, and that obtains a culture supernatant of a cell-containing product by removing cells from the culture fluid using a cell removal filter. The purification unit includes a purification process using a purification filter of a one-way tangential flow filtration method, a sterile filter having a larger aperture than the cell removal filter is provided on the connection line, and the culture supernatant flowing from the culture unit through the connection line into the purification unit is filtered by the sterile filter.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The technology of the present invention relates to a method for manufacturing a biopharmaceutical API, a system for manufacturing a biopharmaceutical API, and a biopharmaceutical API. Background Art

[0002] The following method is widely performed: by culturing cells such as antibody-forming cells that integrate antibody genes into Chinese hamster ovary cells (CHO cells (Chinese Hamster Ovary cells)) to obtain cell products such as antibodies, and by purifying the products to obtain the raw materials of biopharmaceuticals. In the past, in the manufacture of such raw materials of biopharmaceuticals, batch production was carried out, and the batch production was carried out separately. The cell culture process and the product purification process were carried out, but in recent years, continuous production has become the mainstream instead of batch production. Continuous production is a method in which the culture process and the purification process are carried out continuously by physically connecting the culture part and the purification part, the culture part carries out a culture process including a culture tank, etc., and the purification part carries out a purification process including a chromatographic device, etc. Compared with batch production, the quality and productivity of the raw materials can be greatly improved according to this continuous production.

[0003] A manufacturing system for a raw material drug of a biopharmaceutical based on continuous production is recorded in Japanese Patent Publication No. 2020-033364 and Japanese Patent Table No. 2018-518161. In the manufacturing system recorded in Japanese Patent Publication No. 2020-033364 and Japanese Patent Table No. 2018-518161, a sterile filter is provided between the culture unit and the purification unit. The sterile filter filters the culture supernatant flowing from the culture unit into the purification unit. The culture supernatant is obtained by removing cells from the culture fluid of the cells through a cell removal filter provided in the culture unit, and mainly comprises a product. According to the sterile filter, it is possible to prevent bacteria from invading the culture unit from the purification unit, and it is possible to reduce concerns about the contamination of the culture supernatant.

[0004] In Japanese Patent Publication No. 2020-033364 and Japanese Patent Table No. 2018-518161, 0.2 μm is exemplified as the pore size of the cell removal filter located upstream. In addition, in Japanese Patent Publication No. 2020-033364 and Japanese Patent Table No. 2018-518161, as the pore size of the sterile filter located downstream, 0.2 μm, which is the same as the cell removal filter, or a larger value than the cell removal filter is exemplified. In addition, in Japanese Patent Publication No. 2020-033364 and Japanese Patent Table No. 2018-518161, the purification process is mainly carried out by a chromatographic device. Summary of the invention

[0005] Technical issues to be solved by the invention

[0006] When the pore size of the sterile filter is the same as or larger than that of the cell removal filter as in Japanese Patent Publication No. 2020-033364 and Japanese Patent Table No. 2018-518161, the load applied to the sterile filter located downstream can be reduced. Therefore, failures such as clogging are less likely to occur in the sterile filter, and maintainability is improved.

[0007] However, when the purification process is mainly performed by a chromatography apparatus, maintainability is reduced for reasons such as the susceptibility to failure.

[0008] One embodiment of the technology according to the present invention provides a method for producing a biopharmaceutical API, a system for producing a biopharmaceutical API, and a biopharmaceutical API that can suppress a decrease in maintainability.

[0009] Means for solving technical problems

[0010] In the method for producing a biopharmaceutical API of the present invention, a culture section and a purification section are connected by a connecting pipeline, the culture section performs a culture process, the culture process cultivates cells in a culture solution stored in a culture tank, and obtains a culture supernatant containing a cell product by removing cells from the culture solution using a cell removal filter, the purification section performs a purification process, the purification process obtains a biopharmaceutical API by purifying a product from the culture supernatant, the purification section includes a purification process using a purification filter in a single-pass tangential flow filtration method, a sterile filter having a larger pore size than the cell removal filter is set on the connecting pipeline, and the culture supernatant flowing from the culture section through the connecting pipeline into the purification section is filtered by the sterile filter.

[0011] The next step after the purification process using the purification filter of the single-pass tangential flow filtration method is preferably a purification process using a chromatography device.

[0012] The chromatographic device is preferably a single column.

[0013] In addition to the sterile filter provided on the connecting line, it is preferred to use a sterile filter connected in parallel with the connecting line.

[0014] When the maximum capacity of the culture tank is MCC and the filtration area of ​​the sterile filter is FA, it is preferably 0.001 m 2 / L≤(FA / MCC)≤0.01m 2 / L.

[0015] The pore size of the sterile filter is preferably larger than the pore size of the purification filter in the single-pass tangential flow filtration method and is 0.1 μm or more and 1.0 μm or less.

[0016] The sterile filter is preferably a structure obtained by folding flat filter paper.

[0017] The sterile filter is preferably a structure in which hollow fibers are bundled.

[0018] The material of the sterile filter is preferably polyethersulfone.

[0019] The culture supernatant is preferably transferred from the culture section to the purification section by a transfer pump provided upstream of the sterile filter in the connection line.

[0020] The culture supernatant is preferably temporarily stored in an intermediate container provided downstream of the sterile filter in the connecting line.

[0021] The flow rate of the culture supernatant flowing into the sterile filter is preferably constant.

[0022] When the cumulative flow rate of the culture supernatant flowing into the sterile filter reaches 1000 L / m 2 ~10000L / m 2 It is preferred to replace the sterile filter between set volumes.

[0023] The flow rate of the culture supernatant flowing into the purification filter is preferably varied by 50% or more at set intervals set between 2 minutes and 30 minutes.

[0024] The culture supernatant is preferably allowed to flow into a sampling container connected to a connection line downstream of the sterile filter.

[0025] Preferably, the culture supernatant is caused to flow into the sampling container by a supply pump provided on a branch line connecting the connection line and the sampling container.

[0026] The product is preferably a protein.

[0027] The cells are preferably cells derived from Chinese hamster ovary cells.

[0028] The manufacturing system of the raw material drug of the biopharmaceutical of the present invention comprises: a culture section, which performs a culture process, wherein the culture process cultivates cells in a culture solution stored in a culture tank, and obtains a culture supernatant containing a cell product by removing the cells from the culture solution using a cell removal filter; a purification section, which performs a purification process, wherein the product is purified from the culture supernatant to obtain the raw material drug of the biopharmaceutical, and the purification section includes a purification process using a purification filter in a single-pass tangential flow filtration method; a connecting line connecting the culture section and the purification section; and a sterile filter, which is arranged in the connecting line, the sterile filter has a larger pore size than the cell removal filter, and filters the culture supernatant that flows from the culture section into the purification section through the connecting line.

[0029] The biopharmaceutical raw material drug of the present invention is produced by the above-described method for producing a biopharmaceutical raw material drug.

[0030] Effects of the Invention

[0031] According to the technology of the present invention, it is possible to provide a method for producing a biopharmaceutical API, a system for producing a biopharmaceutical API, and a biopharmaceutical API that can suppress a decrease in maintainability. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 This is a diagram showing a manufacturing system for a biopharmaceutical API.

[0033] Figure 2 It is a figure which shows the surroundings of a sterile filter.

[0034] Figure 3 It is a diagram showing the structure of a sterile filter and an intermediate container.

[0035] Figure 4 This is a block diagram of a computer that constitutes the control device.

[0036] Figure 5 This is a block diagram of the CPU of the computer constituting the control device.

[0037] Figure 6 It is a diagram showing the temporal change in the amount of the culture supernatant in the intermediate container, the operation timing of the first supply pump, and the operation timing of the purification unit.

[0038] Figure 7 This is a flowchart showing the processing procedure of the control device.

[0039] Figure 8 This is a diagram showing another example of the method for measuring the amount of the culture supernatant.

[0040] Fig. 9 This is a graph showing the temporal change in the flow rate of the culture supernatant flowing into the purification filter of the single-pass tangential flow filtration system.

[0041] Fig.10 Yes means Fig. 9 The example shown is a graph showing changes in the amount of the culture supernatant in the intermediate container over time.

[0042] Fig.11 This is a diagram showing a second embodiment using a plurality of sterile filters.

[0043] Fig.12 It is a diagram showing an intermediate control unit according to the second embodiment.

[0044] Fig.13FIG. 1 is a diagram showing the processing of the intermediate control unit according to the second embodiment. Fig.13 A represents the situation before the cumulative flow rate of the culture supernatant flowing into the sterile filter of the connection path reaches the set amount, Fig.13 B represents a case where the accumulated flow rate of the culture supernatant into the sterile filter of the connection path reaches the set amount.

[0045] Fig.14 This is a diagram showing another example of a sterile filter. DETAILED DESCRIPTION

[0046] [First embodiment]

[0047] As an example, Figure 1 As shown, a biopharmaceutical API manufacturing system 2 for implementing a method for manufacturing a biopharmaceutical API according to the technology of the present invention comprises a culture section 10 for performing a culture process, an intermediate section 11, a purification section 12 for performing a purification process, and a control device 13. The culture section 10 has a culture tank 14 and a cell removal filter 15. A culture solution (also referred to as a culture fluid) 16 is stored in the culture tank 14. Antibody-forming cells 17 are inoculated into the culture tank 14, and the antibody-forming cells 17 are cultured in the culture fluid 16.

[0048] Antibody-forming cells 17 are, for example, cells established by integrating antibody genes into cells such as Chinese hamster ovary cells. That is, antibody-forming cells 17 are an example of "cells derived from Chinese hamster ovary cells" involved in the technology of the present invention. Antibody-forming cells 17 produce immunoglobulins, namely antibodies 18, as products during the culture process. Therefore, not only antibody-forming cells 17 but also antibodies 18 are present in the culture medium. Antibodies 18 are, for example, monoclonal antibodies, which become active ingredients of biopharmaceuticals. In addition, antibodies 18 are an example of "proteins" involved in the technology of the present invention.

[0049] The culture tank 14 is provided with a culture solution supply channel 19, a gas supply channel 20, an exhaust channel 21, a culture solution transport / recovery channel 22, a distributor 23, a gas supply channel 24 and a stirring blade 25. As shown by arrow A, the culture solution supply channel 19 is a flow path for continuously supplying fresh culture solution 16 in the culture tank 14. That is, the culture section 10 performs perfusion culture. As shown by arrow B, the gas supply channel 20 is a flow path for supplying a gas containing air and carbon dioxide from the upper part. As shown by arrow C, the exhaust channel 21 is a flow path for discharging the gas supplied from the gas supply channel 20 to the outside of the culture tank 14. An exhaust filter 26 is provided in the exhaust channel 21.

[0050] The culture solution delivery / recovery channel 22 is connected to the inlet and outlet 27 of the cell removal filter 15. As shown by arrow D, the culture solution delivery / recovery channel 22 is a flow path for delivering the culture solution 16 in the culture tank 14 to the cell removal filter 15. And, as shown by arrow E, the culture solution delivery / recovery channel 22 is a flow path for returning the culture solution 16 (concentrated solution) from the cell removal filter 15 to the culture tank 14. In addition, although not shown in the figure, a pump for supplying the culture solution 16 to the culture tank 14 is provided in the culture solution supply channel 19.

[0051] The distributor 23 is arranged at the bottom of the culture tank 14. As shown by the arrow F, the distributor 23 releases the oxygen-containing gas supplied from the gas supply channel 24 into the culture tank 14. The oxygen released from the distributor 23 dissolves in the culture solution 16, which helps the activity of the antibody-forming cells 17 to form antibodies 18. The stirring blade 25 is rotated at a predetermined speed by a motor or the like to stir the culture solution 16 in the culture tank 14. Thus, the uniformity of the culture solution 16 in the culture tank 14 is maintained. In addition to these, a flow path for intentionally extracting a portion of the culture solution 16 for cell bleed treatment is also provided in the culture tank 14. In addition, the stirring blade 25 may have a plurality of blades as shown in the figure, or may have a single disc-shaped blade, and the shape is not particularly limited. Furthermore, more than two stirring blades 25 may be arranged in the culture tank 14.

[0052] The cell removal filter 15 has a filter membrane 28 inside. The filter membrane 28 captures the antibody-forming cells 17 and allows the antibodies 18 to pass through. The cell removal filter 15 obtains the culture supernatant 29 by removing the antibody-forming cells 17 from the culture solution 16 using the filter membrane 28, for example, by tangential flow filtration (TFF: Tangential Flow Filtration). The pore size of the filter membrane 28 is not particularly limited as long as it is a size that can remove cells such as antibody-forming cells 17 from the culture solution 16, but it can be 0.01 μm or more and 0.5 μm or less, preferably 0.1 μm or more and 0.4 μm or less, and particularly preferably 0.15 μm or more and 0.3 μm or less. In one example, the pore size of the filter membrane 28 is 0.2 μm. In addition, the pore size mentioned here means the average pore size. The average pore size can be measured by mercury intrusion.

[0053] In more detail, the cell removal filter 15 has a diaphragm pump 31 and a degassing / air supplying channel 32 inside the elastic membrane 30. While air on the lower side of the elastic membrane 30 is degassed from the degassing / air supplying channel 32, the elastic membrane 30 is elastically deformed so as to be attached to the lower end of the diaphragm pump 31, whereby the culture solution 16 in the culture tank 14 flows into the cell removal filter 15 via the culture solution delivery / recovery channel 22. Furthermore, while air is supplied from the degassing / air supplying channel 32 to the lower side of the elastic membrane 30, the elastic membrane 30 is elastically deformed so as to be attached to the upper side of the diaphragm pump 31, whereby the culture solution 16 (concentrated solution) that cannot pass through the filter membrane 28 is returned to the culture tank 14 via the culture solution delivery / recovery channel 22.

[0054] As shown by arrow G, the culture supernatant 29 flows out from the outlet 33 of the cell removal filter 15. The culture supernatant 29 mainly contains the antibody 18. In addition to the antibody 18, the culture supernatant 29 also includes foreign substances such as cell-derived proteins / cell-derived DNA (Deoxyribonucleic Acid) and aggregates of the antibody 18, viruses, and the like.

[0055] The connection path 34 is connected to the outlet 33 of the cell removal filter 15. The connection path 34 is provided with a delivery pump 35 and a flow meter 36. The delivery pump 35 delivers the culture supernatant 29 flowing out of the outlet 33 toward the downstream intermediate section 11 and the purification section 12. The flow meter 36 measures the flow rate of the culture supernatant 29 flowing through the connection path 34.

[0056] In the middle part 11, the connection path 34 is aseptically connected to the connection path 41 and the branch path 42 through the three-way joint 40. A pinch valve 43 and a sterile filter 44 are provided on the connection path 41. The pinch valve 43 and the sterile filter 44 are provided in the connection path 41 at a position downstream of the three-way joint 40 which is the connection portion with the branch path 42.

[0057] The pinch valve 43 is a valve for switching the flow path of the culture supernatant 29 from the connection path 41 to the branch path 42. The pinch valve 43 is a valve that closes the connection path 41 by, for example, squeezing the tube constituting the connection path 41 from the outside with a valve body through the action of a coil and a movable iron core. The pinch valve 43 blocks the flow of the culture supernatant 29 from the culture section 10 to the purification section 12 via the connection path 41 by squeezing the tube constituting the connection path 41. In this way, the pinch valve 43 is a method of clamping the tube from the outside, and the flow path can be switched without contacting the culture supernatant 29. In addition, the other pinch valves 50 and 70 described later also have the same structure and function as the pinch valve 43, except that the tube squeezing by the valve body is different, and therefore, detailed description is omitted. In addition, the tube of the pinch valve 56 described later also has the same structure and function as the pinch valve 43 except that the tube squeezing by the valve body is different and it is manually operated, and therefore, detailed description is omitted.

[0058] The sterile filter 44 filters the culture supernatant 29 flowing into the purification section 12. The sterile filter 44 has built-in filter membranes 99 and 100 (both refer to Figure 3 ). The filter membrane 100 has a smaller pore size than the filter membrane 99. The pore sizes of the filter membranes 99 and 100 satisfy the following conditions respectively.

[0059] Pore ​​diameter of the filter membrane 99: 0.4 μm or more and 2.0 μm or less, preferably 0.4 μm or more and 1.0 μm or less

[0060] Pore ​​diameter of the filter membrane 100: 0.1 μm or more and 1.0 μm or less, preferably 0.1 μm or more and 0.3 μm or less

[0061] A storage tank 45 is connected to the branch path 42. When a certain failure occurs in the purification unit 12, the storage tank 45 temporarily stores the culture supernatant 29 from the culture unit 10. The storage tank 45 is formed by molding a resin film such as polyolefin (PO) or ethylene-vinyl acetate (EVA) copolymer into a rectangular parallelepiped shape, and has flexibility. In addition, the storage tank 45 is a disposable product that is used only once.

[0062] The storage tank 45 has a capacity of 0.2 times or more and 10 times or less of the amount of the culture solution 16 in the culture tank 14. Therefore, for example, when the amount of the culture solution 16 is 50 L, the capacity of the storage tank 45 is 10 L to 500 L. Also, for example, when the amount of the culture solution 16 is 5000 L, the capacity of the storage tank 45 is 1000 L to 50000 L.

[0063] A sterile connector 46 is provided at the front end of the branch path 42. In addition, a sterile connector 49 is also provided at the front end of the inflow tube 48 connected to the inflow port 47 of the culture supernatant 29 of the storage tank 45. Through these sterile connectors 46 and 49, the branch path 42, the inflow tube 48, and the storage tank 45 can be aseptically connected. Through these sterile connectors 46 and 49 and the three-way joint 40, etc., all the flow paths from the culture section 10 to the culture supernatant 29 of the storage tank 45 can be aseptically connected. In addition, as the sterile connector 46 and the like (including the sterile connectors 53, 55, 65 and 68, etc. described later), for example, ReadyMate manufactured by GLOBAL LIFE SCIENCESTECHNOLOGIES JAPAN KK can be used. TM DAC (Disposable Aseptic Connector).

[0064] A pinch valve 50 is provided on the branch path 42 . The pinch valve 50 is a valve for allowing the culture supernatant 29 to flow into the tank 45 via the branch path 42 .

[0065] A liquid level sensor (not shown) is provided in the tank 45. When the liquid level sensor detects that the culture supernatant 29 has reached a predetermined level, a signal indicating that the tank 45 is filled with the culture supernatant 29 is transmitted to the control device 13.

[0066] A discharge port 51 is provided at the bottom of the storage tank 45. A discharge pipe 52 is connected to the discharge port 51. A sterile connector 53 is provided at the front end of the discharge pipe 52. A waste liquid channel 54 is connected to the discharge pipe 52. A sterile connector 55 is provided at the front end of the waste liquid channel 54. Through these sterile connectors 53 and 55, the discharge pipe 52, the storage tank 45 and the waste liquid channel 54 can be connected aseptically.

[0067] A manual pinch valve 56 is provided in the waste liquid channel 54. When the pinch valve 56 is opened, the culture supernatant 29 temporarily stored in the storage tank 45 is discharged into the waste liquid storage tank (not shown) via the discharge port 51, the discharge pipe 52 and the waste liquid channel 54. In addition, the culture supernatant 29 from the culture section 10 is not directly discharged into the waste liquid channel 54, but is temporarily stored in the storage tank 45 and then discharged into the waste liquid channel 54 in order to prevent contamination from the waste liquid channel 54. Although not shown, a sterile filter may be provided between the waste liquid channel 54 and the waste liquid storage tank.

[0068] After the pinch valve 56 is manually opened to discharge the culture supernatant 29, the tank 45 is separated from the branch path 42 by removing the sterile connector 49 from the sterile connector 46. The sterile connector 49 of a new tank 45 is attached to the sterile connector 46. Thus, the used tank 45 is replaced with a new tank 45.

[0069] In addition, a branch path may be further connected to the upstream side of the pinch valve 50 of the branch path 42, so that a plurality of tanks 45 can be connected. Furthermore, the tank 45 may be connected to the connection path 41, and the culture supernatant 29 temporarily stored in the tank 45 may be returned to the connection path 41 to flow into the purification section 12.

[0070] Downstream of the sterile filter 44, the connection path 41 is aseptically connected to the connection path 58 and the branch path 59 through a three-way joint 57. An intermediate container 60 is connected to the connection path 58. The intermediate container 60 temporarily stores the culture supernatant 29 just before the purification section 12. A connection path 61 is connected to the intermediate container 60. The connection path 61 is connected to the purification section 12. A first supply pump 62 and a flow meter 63 are provided on the connection path 61. The first supply pump 62 supplies the culture supernatant 29 in the intermediate container 60 to the purification section 12. The flow meter 63 measures the flow rate of the culture supernatant 29 flowing through the connection path 61, that is, the culture supernatant 29 flowing into the purification section 12. In addition, the connection paths 34, 41, 58 and 61 are examples of the "connection pipeline" involved in the technology of the present invention.

[0071] A sampling container 64 is connected to the branch path 59. The branch path 59 is an example of a "branch line" involved in the technology of the present invention. The sampling container 64 is a container provided for collecting a small amount of culture supernatant 29 for sampling the concentration of the antibody 18 in the culture supernatant 29. Similar to the storage tank 45, the sampling container 64 is formed by molding a resin film such as polyolefin or ethylene-vinyl acetate copolymer into a rectangular parallelepiped shape and has flexibility. Also, similar to the storage tank 45, the sampling container 64 is a disposable product that is used only once. However, compared with the storage tank 45, the capacity of the sampling container 64 is smaller.

[0072] A sterile connector 65 is provided at the front end of the branch path 59. Furthermore, a sterile connector 68 is also provided at the front end of the inflow tube 67 connected to the inflow port 66 of the culture supernatant 29 of the sampling container 64. Through these sterile connectors 65 and 68, the branch path 59, the inflow tube 67, and the sampling container 64 can be connected in an aseptic manner.

[0073] The branch path 59 is provided with a second supply pump 69 and a pinch valve 70. The second supply pump 69 introduces the culture supernatant 29 flowing through the connection path 41 into the branch path 59. The pinch valve 70 is a valve for allowing the culture supernatant 29 introduced into the branch path 59 by the second supply pump 69 to flow into the sampling container 64. The second supply pump 69 is an example of a “supply pump” involved in the technology of the present invention.

[0074] After a sufficient amount of the culture supernatant 29 is flowed into the sample, the sampling container 64 is separated from the branch path 59 by removing the sterile connector 68 from the sterile connector 65. The separated sampling container 64 is hung on a sampling device such as an antibody concentration measuring device. The sterile connector 68 of a new sampling container 64 is mounted on the sterile connector 65. Thus, the used sampling container 64 is replaced with a new sampling container 64. In addition, similarly to the storage tank 45, a branch path may be further connected between the second supply pump 69 of the branch path 59 and the pinch valve 70, so that a plurality of sampling containers 64 can be connected.

[0075] The purification section 12 includes a SPTFF device 80 and an immunoaffinity chromatography device 81, etc., and the culture supernatant 29 is continuously purified by these devices 80 and 81, etc. The culture supernatant 29 flows into the SPTFF device 80 via the connection path 61. The SPTFF device 80 has a purification filter 82 of the SPTFF method. The purification filter 82 is composed of a plurality of ultrafiltration (UF: Ultrafiltration) membranes connected in series. According to the purification filter 82, the antibody 18 can be fully concentrated by passing the culture supernatant 29 only once without circulating the culture supernatant 29. The SPTFF device 80 generates a first purified solution 83 by extracting the antibody 18 from the culture supernatant 29 using the purification filter 82.

[0076] The first purified solution 83 extracted using the purification filter 82 flows into the immunoaffinity chromatography device 81. The immunoaffinity chromatography device 81 generates a second purified solution 84 by extracting the antibody 18 from the culture supernatant 29 using a column in which a ligand such as protein A or protein G having affinity for the antibody 18 is fixed on a carrier. That is, the first process of the purification unit 12 is a purification process using the purification filter 82 of the SPTFF method, and the next process is a purification process using the immunoaffinity chromatography device 81 of a single column.

[0077] The second purified solution 84 is subjected to a virus inactivation treatment (hereinafter referred to as virus inactivation treatment) 85. After the second purified solution 84 subjected to the virus inactivation treatment 85 is further purified by an ion affinity chromatography device 86 having a column with a cation exchanger as a stationary phase and / or a column with an anion exchanger as a stationary phase, the virus is removed by passing through a filter 87. Then, the second purified solution 84 is subjected to ultrafiltration by a filter 88 and concentration / filtration by diafiltration (DF: Diafiltration). Thus, a raw material drug 89 of a biopharmaceutical can be obtained. In this way, by sequentially performing component separation treatment using the SPTFF device 80 and the immunoaffinity chromatography device 81, impurities and viruses are gradually removed from the culture supernatant 29, and the purity of the antibody 18 is gradually improved. In this way, the purification section 12 is a part that drives the SPTFF device 80 and the like to intentionally concentrate the purification object such as the antibody 18 and remove impurities other than the purification object such as the virus.

[0078] As an example, Figure 2 As shown, the sterile filter 44 is provided with an inlet tube 91 having a sterile connector 90 and an outlet tube 93 having a sterile connector 92. On the other hand, sterile connectors 94 and 95 are provided on the upstream side and the downstream side of the connection path 41. By connecting the sterile connector 90 to the sterile connector 94 and connecting the sterile connector 92 to the sterile connector 95, the sterile filter 44 can be mounted on the connection path 41. Through these sterile connectors 90, 92, 94 and 95, the sterile filter 44 and the connection path 41 can be connected in a sterile manner.

[0079] A cumulative flow meter 96 for measuring the cumulative flow rate of the culture supernatant 29 is built into the sterile filter 44. In addition, an indicator 97 is provided on the sterile filter 44 for reporting when the cumulative flow rate of the culture supernatant 29 measured by the cumulative flow meter 96 reaches a set amount. The indicator 97 is, for example, a rotating disk having a white background and a red background, which displays a white background when the cumulative flow rate of the culture supernatant 29 has not reached the set amount, and displays a red background when the cumulative flow rate of the culture supernatant 29 reaches the set amount. Alternatively, the indicator 97 is a light-emitting element such as an LED (Light-Emitting Diode). The set amount is 1000 L / m 2 ~10000L / m 2 In addition, the integrating flow meter 96 may not be built in the sterile filter 44, and may be provided separately from the sterile filter 44 and upstream of the sterile filter 44.

[0080] When the accumulated flow rate of the culture supernatant 29 reaches the set amount, the sterile filter 44 is separated from the connection path 41 by removing the sterile connectors 90 and 92 from the sterile connectors 94 and 95. The sterile connectors 90 and 92 with new sterile filters 44 are attached to the sterile connectors 94 and 95. Thus, the sterile filter 44 whose accumulated flow rate of the culture supernatant 29 reaches the set amount is replaced with a new sterile filter 44.

[0081] As an example, Figure 3 As shown, the flow rate of the culture supernatant 29 flowing into the sterile filter 44 by the delivery pump 35 is constant. In addition, in addition to being completely constant, "constant" means constant in the sense of including errors that are generally allowed in the technical field to which the technology of the present invention belongs and that do not deviate from the technical spirit of the present invention. In the technology of the present invention, "constant" means that the flow rate of the culture supernatant 29 flowing into the sterile filter 44 can be within ±20% of the target value, preferably within ±10%.

[0082] The sterile filter 44 has filter membranes 99 and 100. The filter membranes 99 and 100 are structures formed by folding flat filter paper made of polyethersulfone. The sterile filter 44 having such filter membranes 99 and 100 is called a flat membrane filter.

[0083] When the maximum capacity of the culture tank 14 is set to MCC and the filtration area of ​​the filter membranes 99 and 100 of the sterile filter 44 is set to FA, the ratio FA / MCC of the maximum capacity MCC of the culture tank 14 to the filtration area FA of the filter membranes 99 and 100 only needs to be within the range of the following formula (1), and is more preferably within the range of the following formula (2).

[0084] 0.0004m 2 / L(liter)≤(FA / MCC)≤0.02m 2 / L……(1)

[0085] 0.001m 2 / L≤(FA / MCC)≤0.01m 2 / L……(2)

[0086] The maximum capacity MCC of the culture tank 14 is, for example, 50 L or more and 5000 L or less. Therefore, for example, when the maximum capacity MCC of the culture tank 14 is the lower limit value of 50 L, the filtration area FA of the filter membranes 99 and 100 is 0.05 m 2 Above and 0.5m 2 Furthermore, for example, when the maximum capacity MCC of the culture tank 14 is the upper limit value of 5000 L, the filtration area FA of the filter membranes 99 and 100 is 5 m 2 More than 50m2 the following.

[0087] The intermediate container 60 is a bag formed by sealing two sheets of resin such as polyolefin or ethylene-vinyl acetate copolymer over their entire circumferences and bonding the two sheets of resin in a liquid-tight manner. Similar to the tank 45 and the sampling container 64, the intermediate container 60 is a disposable product that is used only once.

[0088] An inlet 102 is provided at the bottom 101 of the intermediate container 60, into which the culture supernatant 29 flows from the culture section 10. An inlet tube 103 is installed at the inlet 102, and a sterile connector 104 is provided at the front end of the inlet tube 103. A sterile connector 105 is also provided at the front end of the connection path 58. Through these sterile connectors 104 and 105, the connection path 58, the inlet tube 103, and the intermediate container 60 can be connected in an aseptic manner.

[0089] In addition, an outflow port 106 is provided at the bottom 101 of the intermediate container 60, through which the culture supernatant 29 flows out toward the purification section 12. An outflow tube 107 is attached to the outflow port 106, and a sterile connector 108 is provided at the front end of the outflow tube 107. A sterile connector 109 is also provided at the front end of the connection path 61. Through these sterile connectors 108 and 109, the outflow tube 107, the intermediate container 60, and the connection path 61 can be connected in an aseptic manner.

[0090] The intermediate container 60 is separated from the connection paths 58 and 61 by removing the aseptic connectors 104 and 108 from the aseptic connectors 105 and 109. The aseptic connectors 104 and 108 with new intermediate containers 60 are mounted on the aseptic connectors 105 and 109. Thus, the used intermediate container 60 is replaced with a new intermediate container 60.

[0091] The flow rate of the culture supernatant 29 flowing into the inlet 102 by the delivery pump 35 is constant. In addition, the flow rate of the culture supernatant 29 flowing out of the outflow port 106 by the first supply pump 62 is also constant. In addition, the outflow rate of the culture supernatant 29 flowing out of the outflow port 106 is faster than the inflow rate of the culture supernatant 29 flowing into the inflow port 102. In addition, the outflow rate of the culture supernatant 29 flowing out of the outflow port 106 is faster than the inflow rate of the culture supernatant 29 flowing into the inflow port 102 by 1% or more and 30% or less, and more preferably faster by 2% or more and 20% or less.

[0092] A hanging tool 111 is attached to the upper portion 110 of the intermediate container 60. The intermediate container 60 can be hung on a hook 112 by the hanging tool 111 for use. An electronic spring scale 113 is attached to the hook 112. The electronic spring scale 113 measures the amount of the culture supernatant 29 in the intermediate container 60 by measuring the weight of the intermediate container 60 in a state of being hung on the hook 112. The weight of the empty intermediate container 60 and the weight of the hook 112 are stored in advance in the electronic spring scale 113. The electronic spring scale 113 calculates the amount of the culture supernatant 29 in the intermediate container 60 by subtracting the weight of the empty intermediate container 60 and the weight of the hook 112 from the measured weight of the intermediate container 60, and outputs the result as a measurement result. The electronic spring scale 113 sends the measurement result of the liquid amount to the control device 13. In addition, the electronic spring scale 113 is also attached to a hook on a hanging frame (not shown). Alternatively, the weight of the intermediate container 60 may be output from the electronic spring balance 113 to the control device 13 as a measurement result, and the weight may be converted into a liquid volume by the control device 13. Alternatively, the weight of the intermediate container 60 itself may be handled as the liquid volume of the culture supernatant 29.

[0093] As an example, Figure 4 As shown, the computer constituting the control device 13 includes a storage device 120 , a memory 121 , a CPU (Central Processing Unit) 122 , a communication unit 123 , a display 124 , and an input device 125 . These are connected to each other via a bus 126 .

[0094] The storage device 120 is a hard disk drive built into a computer constituting the control device 13 or connected via a cable or a network. Alternatively, the storage device 120 is a disk array formed by connecting a plurality of hard disk drives in series. The storage device 120 stores control programs such as an operating system, various application programs, and various data accompanying these programs. In addition, a solid-state drive may be used instead of a hard disk drive.

[0095] The memory 121 is a working memory used by the CPU 122 to execute processing. The CPU 122 loads the program stored in the storage device 120 into the memory 121 and executes processing according to the program. Thus, the CPU 122 centrally controls each part of the computer. In addition, the memory 121 may be built into the CPU 122.

[0096] The communication unit 123 controls the transmission of various information with external devices. The display 124 displays various screens. Various screens have operation functions based on GUI (Graphical User Interface). The computer constituting the control device 13 receives input of operation instructions from the input device 125 through various screens. The input device 125 is a keyboard, a mouse, a touch panel, a microphone for voice input, etc.

[0097] As an example, Figure 5 As shown, a control program 130 is stored in the storage device 120 of the control apparatus 13. The control program 130 is an application program for causing the computer to function as the control apparatus 13. In addition, the storage device 120 also stores data of various screens displayed on the display 124 and the like.

[0098] When the control program 130 is activated, the CPU 122 of the computer constituting the control device 13 cooperates with the memory 121 and the like to function as a culture section control section 135, an intermediate section control section 136, and a purification section control section 137. The culture section control section 135 controls the operation of the culture section 10, the intermediate section control section 136 controls the operation of the intermediate section 11, and the purification section control section 137 controls the operation of the purification section 12.

[0099] The culture unit control unit 135 receives the measurement result of the flow rate of the culture supernatant 29 from the flowmeter 36. The culture unit control unit 135 controls the flow rate of the culture supernatant 29 based on the measurement result. More specifically, the culture unit control unit 135 sends a control signal for setting the flow rate of the culture supernatant 29 to a preset value to the transfer pump 35. By such control, the flow rate of the culture supernatant 29 flowing into the sterile filter 44 and the flow rate of the culture supernatant 29 flowing into the inlet 102 of the intermediate container 60 become constant. In addition, the culture unit control unit 135 controls the supply amount of the culture solution 16 supplied through the culture solution supply channel 19, the supply amount of the oxygen-containing gas supplied through the sparger 23 and the gas supply channel 24, and the rotation speed of the stirring blade 25.

[0100] The intermediate control unit 136 sends a control signal to the pinch valves 43, 50, and 70. The control signal is a signal that conveys either an indication that current does not flow through the coil of the pinch valve 43 or an indication that current flows. Upon receiving a control signal that conveys an indication that current does not flow through the coil, the pinch valve 43 or the like opens the flow path. On the other hand, upon receiving a control signal that conveys an indication that current flows through the coil, the pinch valve 43 or the like closes the flow path. In the following, a control signal that conveys an indication that current does not flow through the coil is expressed as a control signal (open). Furthermore, a control signal that conveys an indication that current flows through the coil is expressed as a control signal (closed).

[0101] The intermediate control unit 136 receives the measurement result of the flow rate of the culture supernatant 29 from the flow meter 63. The intermediate control unit 136 controls the flow rate of the culture supernatant 29 based on the measurement result. More specifically, the intermediate control unit 136 sends a control signal for setting the flow rate of the culture supernatant 29 to a preset value to the first supply pump 62. Through such control, the flow rate of the culture supernatant 29 flowing out of the outflow port 106 becomes constant.

[0102] When the input device 125 instructs to collect the culture supernatant 29 for sampling, the intermediate section control unit 136 sends a control signal to the second supply pump 69 to operate the second supply pump 69. In addition, the intermediate section control unit 136 sends a control signal (open) to the pinch valve 70. As a result, the culture supernatant 29 flows into the sampling container 64.

[0103] The intermediate section control unit 136 receives the measurement result of the liquid amount of the culture supernatant 29 in the intermediate container 60 from the electronic spring balance 113. According to the measurement result of the liquid amount, the intermediate section control unit 136 operates or stops the first supply pump 62. The intermediate section control unit 136 sends a signal of intention to operate the first supply pump 62 to the purification section control unit 137. In addition, the intermediate section control unit 136 sends a signal of intention to stop the operation of the first supply pump 62 to the purification section control unit 137.

[0104] The purification unit control unit 137 sends a control signal to the SPTFF device 80 and the immunoaffinity chromatography device 81. The SPTFF device 80 and the immunoaffinity chromatography device 81 operate the built-in pumps and valves according to the control signal. In addition, although not shown in the figure, the purification unit control unit 137 also sends a control signal to the ion affinity chromatography device 86.

[0105] In addition, although not shown in the figure, the purification section control section 137 receives an error signal from the SPTFF device 80 or the immunoaffinity chromatography device 81. When a certain failure occurs in the SPTFF device 80 or the immunoaffinity chromatography device 81, the error signal is sent from the SPTFF device 80 or the immunoaffinity chromatography device 81. The purification section control section 137 also receives an error signal from the ion affinity chromatography device 86. The certain failure refers to, for example, a failure of a pump in the SPTFF device 80 or the immunoaffinity chromatography device 81 or a blockage of a column in the immunoaffinity chromatography device 81. The purification section control section 137 sends the error signal to the intermediate section control section 136. In addition, although not shown in the figure, when the failure is resolved, a notification signal indicating the situation is sent from the SPTFF device 80, the immunoaffinity chromatography device 81 or the ion affinity chromatography device 86 to the purification section control section 137.

[0106] When receiving an error signal from the purification section control section 137, the intermediate section control section 136 sends a control signal (close) to the pinch valve 43 and then sends a control signal (open) to the pinch valve 50. As a result, the flow path of the culture supernatant 29 is switched from the connecting path 41 to the branch path 42. That is, when an error signal indicating that a failure has occurred is output from the purification section 12, the intermediate section control section 136 performs control to switch the flow path of the culture supernatant 29 from the connecting path 41 to the branch path 42. The culture supernatant 29 flows into the tank 45 along the branch path 42, the inflow tube 48, and the inflow port 47. In addition, when the failure in the purification section 12 is resolved and a notification signal indicating the failure is received from the SPTFF device 80 or the like, the intermediate section control section 136 performs control such that, after sending a control signal (close) to the pinch valve 50, a control signal (open) is sent to the pinch valve 43 to return the flow path of the culture supernatant 29 from the branch path 42 to the connecting path 41.

[0107] As an example, Figure 6 As shown, based on the measurement result of the liquid amount of the culture supernatant 29 in the intermediate container 60, when it is detected that the liquid amount reaches the preset set amount PL between the storage upper limit UL and the storage lower limit LL of the intermediate container 60, the intermediate section control section 136 operates (turns on) the first supply pump 62 to start the outflow of the culture supernatant 29 through the outflow port 106. When receiving an intention signal to operate the first supply pump 62 from the intermediate section control section 136 along with the start of the operation of the first supply pump 62, the purification section control section 137 operates (turns on) the purification section 12.

[0108] On the other hand, when it is detected that the liquid amount of the culture supernatant 29 in the intermediate container 60 reaches the storage lower limit LL, the intermediate section control section 136 stops (turns off) the operation of the first supply pump 62, and stops the outflow of the culture supernatant 29 through the outflow port 106. When the intention signal to stop the operation of the first supply pump 62 is received from the intermediate section control section 136 along with the stop of the operation of the first supply pump 62, the purification section control section 137 stops (turns off) the operation of the purification section 12. That is, the purification section 12 performs intermittent operation such that it operates while the culture supernatant 29 flows out of the outflow port 106, and stops while the culture supernatant 29 does not flow out of the outflow port 106.

[0109] In addition, when the weight of the intermediate container 60 itself is treated as the liquid volume of the culture supernatant 29, the storage lower limit LL, the storage upper limit UL, and the set amount PL are also treated as the weight of the intermediate container 60. For example, 3 kg is set as the storage range lower limit LL, 7 kg is set as the storage range upper limit UL, and the set amount PL is set to 5 kg. When it is detected that the weight of the intermediate container 60 reaches 5 kg, the intermediate part control unit 136 starts to make the culture supernatant 29 flow out, and when it is detected that the weight of the intermediate container 60 reaches 3 kg, the intermediate part control unit 136 stops the flow of the culture supernatant 29.

[0110] As described above, the flow rate of the culture supernatant 29 flowing from the culture section 10 into the inlet 102 is constant. Therefore, the liquid amount of the culture supernatant 29 increases linearly. Also, as described above, the flow rate of the culture supernatant 29 flowing out from the outlet 106 to the purification section 12 is also constant. Therefore, the liquid amount of the culture supernatant 29 decreases linearly. The slope of the straight line indicating the increase in the liquid amount of the culture supernatant 29 indicates the increase in the liquid amount of the culture supernatant 29 per unit time, that is, the inflow speed of the culture supernatant 29 flowing into the inlet 102. In contrast, the slope of the straight line indicating the decrease in the liquid amount of the culture supernatant 29 indicates the decrease in the liquid amount of the culture supernatant 29 per unit time, but does not coincide with the outflow speed of the culture supernatant 29 flowing out of the outlet 106. This is because the culture supernatant 29 continues to flow in from the inlet 102 even while the culture supernatant 29 flows out of the outlet 106.

[0111] As described above, the outflow speed of the culture supernatant 29 flowing out of the outflow port 106 is faster than the inflow speed of the culture supernatant 29 flowing in from the inflow port 102. Therefore, if the amount of the culture supernatant 29 flowing in from the inflow port 102 is subtracted while the culture supernatant 29 flows out of the outflow port 106, the slope of the straight line indicating the decrease in the amount of the culture supernatant 29 becomes steeper than the slope of the straight line indicating the increase in the amount of the culture supernatant 29. However, in reality, the amount of the culture supernatant 29 flowing in from the inflow port 102 while the culture supernatant 29 is flowing out of the outflow port 106 is also included. In addition, the difference between the inflow speed of the culture supernatant 29 flowing in from the inflow port 102 and the outflow speed of the culture supernatant 29 flowing out of the outflow port 106 is small. Therefore, the slope of the straight line indicating the decrease in the amount of the culture supernatant 29 becomes slower than the slope of the straight line indicating the increase in the amount of the culture supernatant 29 as shown in the figure.

[0112] Here, the flow rate of the culture supernatant 29 flowing out of the outlet 106 to the purification section 12 being constant means that after the first supply pump 62 is operated by the intermediate section control section 136 to start the culture supernatant 29 flowing out through the outlet 106, the operation of the first supply pump 62 is stopped, and the flow rate during the period until the outflow of the culture supernatant 29 through the outlet 106 is stopped is constant.

[0113] When the maximum capacity of the intermediate container 60 is MC, the storage upper limit UL of the intermediate container 60 is within the range of the following formula (3).

[0114] 0.5MC≤UL≤1.0MC……(3)

[0115] Thus, the storage upper limit UL is not necessarily consistent with the maximum capacity MC.

[0116] Furthermore, the storage lower limit LL of the intermediate container 60 is within the range of the following formula (4).

[0117] 0.1MC≤LL<0.5MC……(4)

[0118] In this way, the storage lower limit LL becomes a value greater than zero.

[0119] The set amount PL is expressed by, for example, the following formula (5).

[0120] PL=(UL+LL) / 2……(5)

[0121] Therefore, for example, when the storage upper limit UL is 1.0MC and the storage lower limit LL is 0.2MC, PL = (1.0MC + 0.2MC) / 2 = 0.6MC. In addition, the set amount PL is not limited to the above formula (5). It can be PL = 0.5MC or PL = 0.9MC. For example, PL = 0.9999MC, etc., the set amount PL can also be set to be substantially the same as the maximum capacity MC.

[0122] Next, as an example, refer to Figure 7 The action based on the above structure is explained in the flowchart. First, antibody-forming cells 17 are seeded into the culture tank 14 of the culture unit 10 and cultured in the culture solution 16. Thus, antibodies 18 are formed from the antibody-forming cells 17 and dispersed in the culture solution 16.

[0123] The culture solution 16 is transported to the cell removal filter 15 via the culture solution transport / recovery channel 22 and the inlet and outlet 27. The culture solution 16 removes the antibody-forming cells 17 through the filter membrane 28 of the cell removal filter 15, and becomes a culture supernatant 29. The culture supernatant 29 flows out from the outlet 33 to the connection path 34, and is transported downstream by the transport pump 35. At this time, a control signal corresponding to the measurement result of the flow meter 36 is sent from the culture unit control unit 135 to the transport pump 35, thereby controlling the flow rate of the culture supernatant 29 to be constant according to the measurement result of the flow meter 36.

[0124] The culture supernatant 29 flows from the connection channel 34 into the connection channel 41, and passes through the pinch valve 43 and the sterile filter 44. The sterile filter 44 removes impurities other than the antibody 18 in the culture supernatant 29.

[0125] The culture supernatant 29 that has passed through the sterile filter 44 flows into the inlet 102 of the intermediate container 60 via the connection path 58 and the inlet tube 103, and flows into the intermediate container 60 through the inlet 102. Thus, the culture supernatant 29 is stored in the intermediate container 60.

[0126] like Figure 3 As shown, the liquid volume of the culture supernatant 29 in the intermediate container 60 is measured by the electronic spring balance 113. The measurement result of the liquid volume of the culture supernatant 29 is transmitted from the electronic spring balance 113 to the intermediate part control part 136.

[0127] like Figure 6 As shown, the operation of the first supply pump 62 is stopped by the intermediate section control section 136, and the operation of the purification section 12 is stopped by the purification section control section 137 (step ST100) until the liquid volume of the culture supernatant 29 reaches the set volume PL ( Figure 7 Here, when it is detected that the amount of the culture supernatant 29 reaches the set amount PL ("Yes" in step ST110), the intermediate unit control unit 136 operates the first supply pump 62 to start the culture supernatant 29 flowing out through the outflow port 106. And, the purification unit 12 (step ST120) is operated by the purification unit control unit 137. In the purification unit 12, the antibody 18 in the culture supernatant 29 is continuously purified by the SPTFF device 80 and the immunoaffinity chromatography device 81, and finally the raw material drug 89 of the biopharmaceutical can be obtained.

[0128] The operation of the first supply pump 62 is continued by the intermediate section control section 136, and the operation of the purification section 12 is continued by the purification section control section 137 (step ST120) until the liquid volume of the culture supernatant 29 reaches the storage lower limit LL ("No" in step ST130). Here, when it is detected that the liquid volume of the culture supernatant 29 reaches the storage lower limit LL ("Yes" in step ST130), the intermediate section control section 136 stops the operation of the first supply pump 62 and stops the outflow of the culture supernatant 29 through the outflow port 106. In addition, the operation of the purification section 12 is stopped by the purification section control section 137 (step ST100).

[0129] When no failure occurs in the purification section 12, the intermediate section control section 136 sends a control signal (open) to the pinch valve 43 and a control signal (close) to the pinch valve 50. As a result, the connection path 41 is opened and the branch path 42 is closed. Thus, the culture supernatant 29 flows from the connection path 34 into the connection path 41.

[0130] On the other hand, when a fault occurs in the purification section 12, an error signal is sent from the SPTFF device 80 or the like to the purification section control section 137. The error signal is sent from the purification section control section 137 to the intermediate section control section 136. In this case, after sending a control signal (off) to the pinch valve 43 from the intermediate section control section 136, a control signal (open) is sent to the pinch valve 50. Thus, the connection path 41 is closed and the branch path 42 is opened. In this way, the culture supernatant 29 flows into the storage tank 45. The state in which the culture supernatant 29 flows into the storage tank 45 and is temporarily stored continues until the fault in the purification section 12 is resolved.

[0131] When the fault in the purification section 12 is resolved, a control signal (close) is sent from the intermediate section control section 136 to the pinch valve 50, and then a control signal (open) is sent to the pinch valve 43. As a result, the connection path 41 is opened again, the branch path 42 is closed, and the culture supernatant 29 flows from the connection path 34 into the connection path 41.

[0132] When the input device 125 instructs to collect the culture supernatant 29 for sampling, the intermediate control unit 136 sends a control signal to the second supply pump 69, and the second supply pump 69 is operated. In addition, the intermediate control unit 136 sends a control signal (open) to the pinch valve 70. As a result, the culture supernatant 29 flows into the sampling container 64.

[0133] As described above, the method for producing a raw material drug of a biopharmaceutical according to the technology of the present invention connects the culture section 10 and the purification section 12 through the connection paths 34, 41, 58 and 61. The culture section 10 performs a culture process in which antibody-forming cells 17 are cultured in a culture solution 16 stored in a culture tank 14, and the antibody-forming cells 17 are removed from the culture solution 16 by a cell removal filter 15 to obtain a culture supernatant 29 containing an antibody 18. The purification section 12 performs a purification process in which the antibody 18 is purified from the culture supernatant 29 to obtain a raw material drug 89 of a biopharmaceutical. The purification section 12 includes a purification process using a purification filter 82 of the SPTFF method. Then, a sterile filter 44 having a larger pore size than the cell removal filter 15 is set in the connection path 41, and the culture supernatant 29 flowing from the culture section 10 through the connection path 41 into the purification section 12 is filtered by the sterile filter 44.

[0134] The purification section 12 has the following effects by including a purification process using a purification filter 82 using the SPTFF method. That is, according to the purification process using the purification filter 82 using the SPTFF method, the antibody 18 can be purified by circulating the culture supernatant 29 once. In the previous circulation-type purification process, additional pumps and storage tanks are required, and the operation is also cumbersome. In addition, due to the complex structure, the risk of contamination is also high. In contrast, according to the purification process using the purification filter 82 using the SPTFF method, additional pumps and storage tanks are not required and the operability is good. In addition, due to the simple structure, the risk of contamination is also low. In addition, according to the purification filter 82 using the SPTFF method, impurities in the culture supernatant 29 can be effectively removed. Therefore, the load of the immunoaffinity chromatography device 81 in the rear section can be reduced, and the possibility of failures such as column clogging of the immunoaffinity chromatography device 81 can be reduced. Therefore, the decline in maintainability can be suppressed.

[0135] Furthermore, the sterile filter 44 has a larger pore size than the cell removal filter 15. In other words, the cell removal filter 15 has a smaller pore size than the sterile filter 44. Therefore, most of the impurities in the culture supernatant 29 are removed by the cell removal filter 15. As a result, the load applied to the sterile filter 44 located downstream can be reduced, and failures such as clogging are less likely to occur in the sterile filter 44. Therefore, a decrease in maintainability can be suppressed. Furthermore, frequent failures such as clogging in the sterile filter 44 can be prevented from frequently stopping the continuous purification of the antibody 18 by the purification unit 12. Specifically, continuous purification can be performed for several days to several tens of days without temporarily stopping due to failures of the sterile filter 44.

[0136] In addition to the condition that the sterile filter 44 has a larger pore size than the cell removal filter 15 , the sterile filter 44 may have a double-layered filter membrane having a pore size that satisfies the following conditions.

[0137] Condition: Even if the upstream side load is 10 7 / cm 2 Indicator bacteria can also be obtained on the downstream side, sterile liquid.

[0138] like Figure 1 As shown, the next step of the purification process using the SPTFF purification filter 82 is a purification process using a single column of the immunoaffinity chromatography device 81. Therefore, compared with the case where the purification process is performed using a plurality of chromatography devices each having a different column, the possibility of trouble can be reduced.

[0139] According to the purification filter 82 of the SPTFF method, the antibody 18 can be sufficiently concentrated in a short time compared to the case where a chromatography device is used. Therefore, even if the next process of the purification process using the purification filter 82 of the SPTFF method is a purification process using the immunoaffinity chromatography device 81 of a single column, in other words, even if the next process of the purification process using the purification filter 82 of the SPTFF method is not a purification process using a plurality of chromatography devices having different columns, a highly pure antibody 18 can be obtained.

[0140] Furthermore, the SPTFF purification filter 82 does not require maintenance such as stopping the flow of the culture supernatant 29 for cleaning, as in a chromatographic column, and can continue to flow the culture supernatant 29. Therefore, the system of operating the purification unit 12 while the culture supernatant 29 flows out of the outlet 106 is highly compatible.

[0141] like Figure 3 As shown in the figure, when the maximum capacity of the culture tank 14 is MCC and the filtration area of ​​the sterile filter 44 is FA, 0.001m 2 / L≤(FA / MCC)≤0.01m 2 Therefore, the culture supernatant 29 can be filtered using the sterile filter 44 having a relatively small filtration area FA relative to the maximum capacity MCC of the culture tank 14 .

[0142] like Figure 1 As shown in FIG. 1 , the pore size of the sterile filter 44 is larger than the pore size of the purification filter 82 of the SPTFF device 80. Therefore, the load applied to the sterile filter 44 can be further reduced, and failures such as clogging are less likely to occur in the sterile filter 44. Therefore, the decrease in maintainability can be further suppressed. Figure 1As shown, the pore size of the sterile filter 44 is 0.1 μm or more and 1.0 μm or less. Therefore, impurities in the culture supernatant 29 can be effectively captured.

[0143] like Figure 3 As shown, the sterile filter 44 is a structure formed by folding a flat filter paper. The sterile filter 44 formed by folding a flat filter paper is relatively cheap. Therefore, the cost applied to the sterile filter 44 can be reduced. In addition, the material of the sterile filter 44 is polyethersulfone. Polyethersulfone has high filterability and is not easy to clog. Therefore, the decline in maintainability can be further suppressed.

[0144] like Figure 1 As shown, the culture supernatant 29 is transferred from the culture section 10 to the purification section 12 by a transfer pump 35 provided upstream of the sterile filter 44 on a connection line such as a connection path 34. Compared with a case where the transfer pump 35 is provided downstream of the sterile filter 44, the possibility of a malfunction such as clogging of the sterile filter 44 by bubbles from the transfer pump 35 can be reduced.

[0145] like Figure 1 As shown, the culture supernatant 29 is temporarily stored in an intermediate container 60 provided downstream of the sterile filter 44 on a connection line such as the connection path 34. Therefore, the culture supernatant 29 can be continuously purified by the purification unit 12 without delay.

[0146] like Figure 3 As shown, the flow rate of the culture supernatant 29 flowing into the sterile filter 44 is constant. Therefore, the state of the culture supernatant 29 flowing into the sterile filter 44 can be kept constant.

[0147] like Figure 2 As shown in FIG. 1 , when the cumulative flow rate of the culture supernatant 29 flowing into the sterile filter 44 reaches the setting of 1000 L / m 2 ~10000L / m 2 When the set amount between the accumulated flow rate and the set amount is reached, the sterile filter 44 is replaced. Therefore, the sterile filter 44 whose filtering performance is deteriorated will not be used continuously, and the sterile filter 44 with good filtering performance can be used all the time.

[0148] like Figure 1As shown, the culture supernatant 29 is caused to flow into the sampling container 64 connected to the downstream of the sterile filter 44 on the connection path 41. When the sampling container 64 is connected to the upstream of the sterile filter 44, there is a possibility that bacteria and the like may invade the culture section 10 from the branch path 59 including the sampling container 64 and the like, thereby contaminating the culture section 10. However, in this example, since the invasion of bacteria and the like from the branch path 59 is blocked by the sterile filter 44, the sterile state of the upstream side of the sterile filter 44 can be maintained.

[0149] And, if Figure 1 As shown, the culture supernatant 29 is caused to flow into the sampling container 64 by the second supply pump 69 provided on the branch path 59 connecting the connection paths 41 and 58 and the sampling container 64. Therefore, the culture supernatant 29 can be reliably caused to flow into the sampling container 64. In addition, since the second supply pump 69 functions like a valve, it is possible to suppress the intrusion of bacteria and the like from the downstream side of the second supply pump 69.

[0150] Biopharmaceuticals with antibodies 18 as active ingredients are called antibody drugs, and are widely used in the treatment of chronic diseases such as cancer, diabetes, and rheumatoid arthritis, as well as rare diseases such as hemophilia and Crohn's disease. Therefore, according to this example in which the cells are antibody-forming cells 17 derived from CHO cells and the products are proteins, especially antibodies 18, it is possible to contribute to the development of antibody drugs that are widely used in the treatment of various diseases.

[0151] [Second embodiment]

[0152] As an example, Figure 8 As shown, in the second embodiment, a liquid level sensor 140 is provided on the upper portion 110 of the intermediate container 60. Then, the liquid level sensor 140 detects the position of the liquid surface of the culture supernatant 29 in the intermediate container 60 to measure the liquid amount of the culture supernatant 29 in the intermediate container 60.

[0153] The liquid level sensor 140 is, for example, a reflective optical sensor (also referred to as an optical reflection sensor) that irradiates the measurement light ML toward the liquid surface of the culture supernatant 29 and receives the reflected light of the measurement light ML from the liquid surface of the culture supernatant 29. The liquid level sensor 140 detects the position of the liquid surface of the culture supernatant 29 based on the difference in the intensity of the received reflected light. The liquid level sensor 140 refers to a data table or the like indicating the relationship between the position of the liquid surface of the culture supernatant 29 and the liquid volume of the culture supernatant 29 in the intermediate container 60, converts the detected position of the liquid surface of the culture supernatant 29 into the liquid volume of the culture supernatant 29 in the intermediate container 60, and outputs it as a measurement result. The liquid level sensor 140 sends the measurement result of the liquid volume to the control device 13. Since the following processing is the same as that of the first embodiment, the description thereof is omitted. Alternatively, the position of the liquid surface of the culture supernatant 29 may be output from the liquid level sensor 140 to the control device 13 as the measurement result, and the position of the liquid surface of the culture supernatant 29 may be converted into the liquid volume by the control device 13. Alternatively, similarly to the case of the weight of the intermediate container 60 , the position of the liquid surface itself may be handled as the liquid volume of the culture supernatant 29 .

[0154] Thus, in the second embodiment, the amount of the culture supernatant 29 in the intermediate container 60 is measured by measuring the position of the liquid surface of the culture supernatant 29. Therefore, even in a situation where it is difficult to measure the weight of the intermediate container 60, the amount of the culture supernatant 29 in the intermediate container 60 can be measured. In addition, ultrasonic waves may be used as the liquid level sensor.

[0155] [Third Embodiment]

[0156] In the first embodiment described above, the flow rate of the culture supernatant 29 flowing out from the outflow port 106 to the purification section 12 is set constant, but the present invention is not limited to this.

[0157] As an example, Fig. 9 As shown, in the third embodiment, the intermediate control unit 136 controls the operation of the first supply pump 62 to change the flow rate of the culture supernatant 29 flowing into the purification filter 82 of the SPTFF device 80 at a set interval SI. The set interval SI is set between 2 minutes and 30 minutes (2 minutes ≤ SI ≤ 30 minutes). In addition, the maximum value FRmax of the flow rate of the culture supernatant 29 is more than half of the minimum value FRmin (FRmax ≥ 0.5FRmin). That is, the flow rate of the culture supernatant 29 flowing into the purification filter 82 changes by more than 50%. In this case, as an example, Fig.10 As shown, the amount of the culture supernatant 29 in the intermediate container 60 decreases not in a linear manner but in a broken line manner.

[0158] Thus, in the third embodiment, the flow rate of the culture supernatant 29 flowing into the purification filter 82 is varied by 50% or more at a set interval SI set between 2 minutes and 30 minutes. By thus changing the flow rate of the culture supernatant 29 flowing into the purification filter 82, it is possible to expect a flushing effect of flushing impurities captured by the purification filter 82 by the flowing culture supernatant 29. The purification filter 82 can be efficiently cleaned while purifying the antibody 18.

[0159] When the interval SI is set to be less than 2 minutes, the flushing effect is improved, but the flow rate of the culture supernatant 29 changes too frequently and the antibody 18 cannot be fully concentrated. On the other hand, when the interval SI is set to be longer than 30 minutes, the flushing effect is reduced and clogging is likely to occur in the purification filter 82. In addition, even if the fluctuation range is less than 50%, the flushing effect is reduced and clogging is likely to occur in the purification filter 82. Therefore, the interval SI is set to be between 2 minutes and 30 minutes, and the fluctuation range of the flow rate is set to be 50% or more.

[0160] [Fourth embodiment]

[0161] In the above-mentioned embodiments, the sterile filter 44 is described as one, but the invention is not limited to this. Fig.11 As shown, multiple sterile filters 44 may be used.

[0162] exist Fig.11 , an example using two sterile filters 44A and 44B is shown. In this case, three-way joints 145 and 146 are provided on the upstream side of the pinch valve 43 of the connection path 41 and on the downstream side of the sterile filter 44A. Then, the branch path 147 is connected to the three-way joints 145 and 146, and a pinch valve 148 and a sterile filter 44B are provided on the branch path 147. In addition, although not shown in the figure, the sterile filter 44B is also aseptically connected to the branch path 147 through sterile connectors 90 and 92, etc.

[0163] As an example, Fig.12 As shown in FIG. 1 , in this embodiment, the measurement results of the integrated flow rate of the culture supernatant 29 are input to the intermediate control unit 136 from the integrated flow meter 96A built in the sterile filter 44A and the integrated flow meter 96B built in the sterile filter 44B. The intermediate control unit 136 compares the measurement results of the integrated flow rate of the culture supernatant 29 with the set amount SIF. Figure 2 As described in the above, the set amount SIF is 1000L / m 2 ~10000L / m 2When the measurement result of the integrated flow rate of the culture supernatant 29 reaches the set amount SIF, the intermediate section control section 136 sends a control signal to the pinch valves 43 and 148 .

[0164] Fig.13 A indicates that the control signal (open) is sent from the intermediate control unit 136 to the pinch valve 43, the control signal (closed) is sent to the pinch valve 148, and the culture supernatant 29 is filtered using the sterile filter 44A of the connection path 41. Fig.13 In the state shown in A, when the measurement result of the integrated flow rate of the culture supernatant 29 from the integrated flow meter 96A built in the sterile filter 44A reaches the set flow rate SIF, as shown in FIG. Fig.13 As shown in FIG. 1B , after the intermediate control unit 136 sends a control signal (close) to the pinch valve 43, it sends a control signal (open) to the pinch valve 148. As a result, the flow path of the culture supernatant 29 is switched from the connecting path 41 to the branch path 147, and the culture supernatant 29 flows into the sterile filter 44B of the branch path 147. That is, when the cumulative flow rate of the culture supernatant 29 in one of the plurality of sterile filters 44 reaches the set flow rate SIF, the intermediate control unit 136 switches to use another sterile filter 44.

[0165] Thus, in the fourth embodiment, in addition to the sterile filter 44A provided in the connection path 41, the sterile filter 44B connected in parallel with the connection path 41 is also used. Therefore, it is possible to reduce the process of replacing the sterile filter 44. In addition, the number of the sterile filters 44 connected in parallel with the connection path 41 is not limited to one as shown in the example, but may be two or more.

[0166] [Fifth embodiment]

[0167] In the first embodiment, the sterile filter 44 having the filter membranes 99 and 100 folded from a flat filter paper made of polyethersulfone is exemplified, but the invention is not limited thereto. Fig.14 The sterile filter 150 shown in FIG. 1 has a filter membrane 151 having a structure in which hollow fibers made of polyethersulfone are bundled. The sterile filter 150 having such a filter membrane 151 is called a hollow fiber filter.

[0168] The filter membrane 151 having a structure formed by bundling hollow fibers has a flushing effect. Therefore, according to the sterile filter 150, the frequency of replacement can be reduced compared with the sterile filter 44 having the filter membranes 99 and 100 having a structure formed by folding flat filter paper. In addition, the filter membrane 151 can also be set as a double-layer structure like the filter membranes 99 and 100 of the first embodiment described above.

[0169] In addition, aseptic connector 46 is exemplified as a mechanism for aseptic connection, but it is not limited thereto. Aseptic connection can be performed by heat welding. For example, a biowelder manufactured by Sartorius Stedim Japan KK is used for heat welding (URL (Uniform Resource Locator): https: / / premium.ipros.jp / sartorius-stedim / product / detail / 2000608451 / ?hub=163&categoryId=52772).

[0170] As the non-liquid contact type valve, the pinch valve 43 is exemplified, but the present invention is not limited thereto. A non-electric (manual) pipe clamp may be used in place of the pinch valve 43. As the pipe clamp, a threaded type, an alligator clip type, a roller type, a ratchet type, etc. may be used.

[0171] When a non-electric non-liquid-contacting valve such as a tube clamp is used, an indicator such as a warning light may be provided in the purification section 12 to notify the user of a malfunction in the purification section 12. In this case, an error signal may not be sent from the SPTFF device 80 or the immunoaffinity chromatography device 81 to the purification section control unit 137.

[0172] The product is not limited to the antibody 18. As long as it is a substance that becomes the raw material drug 89 of biopharmaceuticals, it is not particularly limited, and may be proteins other than the antibody 18, peptides, nucleic acids (DNA, RNA (ribonucleic acid)), lipids, viruses, virus subunits, virus-like particles, etc.

[0173] In each of the above-mentioned embodiments, for example, various processors shown below can be used as the hardware structure of the processing unit (Processing Unit) that executes various processes such as the culture unit control unit 135, the intermediate unit control unit 136, and the purification unit control unit 137. As described above, the various processors include a general-purpose processor, i.e., the CPU 122, which executes software (control program 130) to function as various processing units, and processors such as FPGA (Field Programmable Gate Array) whose circuit structure can be changed after manufacturing, i.e., programmable logic devices (PLD), ASIC (Application Specific Integrated Circuit), etc., which have a circuit structure specially designed for executing specific processes, i.e., dedicated circuits.

[0174] One processing unit may be composed of one of these various processors, or a combination of two or more processors of the same or different types (for example, a combination of multiple FPGAs and / or a combination of a CPU and an FPGA). Furthermore, multiple processing units may be composed of one processor.

[0175] As an example of a plurality of processing units constituted by one processor, there is the following method: as represented by computers such as clients and servers, one processor is constituted by a combination of one or more CPUs and software, and the processor functions as a plurality of processing units. Second, there is the following method: as represented by a system on chip (SoC), a processor that implements the functions of the entire system including a plurality of processing units through one IC (Integrated Circuit) chip is used. In this way, various processing units are constituted as a hardware structure using one or more of the above-mentioned various processors.

[0176] Furthermore, more specifically, as the hardware configuration of these various processors, a circuit (circuitry) formed by combining circuit elements such as semiconductor elements can be used.

[0177] The technology of the present invention can also appropriately combine the various embodiments and / or various variations described above. Furthermore, it is not limited to the above embodiments, and various structures can be adopted as long as they do not deviate from the main purpose. In addition, the technology of the present invention also relates to a storage medium that stores programs non-temporarily, in addition to the program.

[0178] The above-described contents and illustrated contents are detailed descriptions of the parts involved in the technology of the present invention, and the technology of the present invention is only an example. For example, the description of the above-described structure, function, action and effect is a description of an example of the structure, function, action and effect of the parts involved in the technology of the present invention. Therefore, without departing from the scope of the technical purpose of the present invention, it is of course possible to delete unnecessary parts of the above-described contents and illustrated contents, or to add or replace them with new elements. In addition, in order to avoid confusion and facilitate understanding of the parts involved in the technology of the present invention, the description of technical common sense that does not need to be specifically described in the technology that can implement the present invention is omitted in the above-described contents and illustrated contents.

[0179] In this specification, "A and / or B" has the same meaning as "at least one of A and B". That is, "A and / or B" may mean only A, only B, or a combination of A and B. Furthermore, in this specification, when three or more items are connected and expressed with "and / or", the same consideration method as "A and / or B" is also applicable.

[0180] All documents, patent applications, and technical standards described in this specification are incorporated herein by reference to the same extent as if each document, patent application, or technical standard was specifically and individually indicated to be incorporated by reference.

Claims

1. A method for producing a biopharmaceutical API, wherein: The culture section and the purification section are connected by a connecting pipeline, the culture section performs a culture process, the culture process cultivates cells in a culture solution stored in a culture tank, and obtains a culture supernatant containing a product of the cells by removing the cells from the culture solution using a cell removal filter, the purification section performs a purification process, the purification process obtains a biopharmaceutical raw material by purifying the product from the culture supernatant, and the purification section includes a purification process using a purification filter of a single-pass tangential flow filtration method, A sterile filter having a larger pore size than the cell removal filter is arranged on the connecting pipeline, The culture supernatant flowing from the culture section through the connecting line into the purification section is filtered through the sterile filter.

2. The method for producing a biopharmaceutical API according to claim 1, wherein: The next step of the purification process using the purification filter in a single-pass tangential flow filtration method is a purification process using a chromatography device.

3. The method for producing a biopharmaceutical API according to claim 2, wherein: The chromatographic device is a single column.

4. The method for producing a biopharmaceutical API according to any one of claims 1 to 3, wherein: In addition to the sterile filter provided on the connecting line, a sterile filter connected in parallel to the connecting line is used.

5. The method for producing a biopharmaceutical API according to any one of claims 1 to 4, wherein: When the maximum capacity of the culture tank is MCC and the filtration area of ​​the sterile filter is FA, it is 0.001 m 2 / L≤(FA / MCC)≤0.01m 2 / L.

6. The method for producing a biopharmaceutical API according to any one of claims 1 to 5, wherein: The pore size of the sterile filter is larger than the pore size of the purification filter in the single-pass tangential flow filtration mode.

7. The method for producing a biopharmaceutical API according to any one of claims 1 to 6, wherein: The pore diameter of the sterile filter is 0.1 μm or more and 1.0 μm or less.

8. The method for producing a biopharmaceutical API according to any one of claims 1 to 7, wherein: The sterile filter has a structure obtained by folding flat filter paper.

9. The method for producing a biopharmaceutical API according to any one of claims 1 to 7, wherein: The sterile filter is a structure formed by bundling hollow fibers.

10. The method for producing a biopharmaceutical API according to any one of claims 1 to 9, wherein: The material of the sterile filter is polyethersulfone.

11. The method for producing a biopharmaceutical API according to any one of claims 1 to 10, wherein: The culture supernatant is transferred from the culture section to the purification section by a transfer pump provided on the connection line upstream of the sterile filter.

12. The method for producing a biopharmaceutical API according to any one of claims 1 to 11, wherein: The culture supernatant is temporarily stored in an intermediate container provided downstream of the sterile filter on the connecting line.

13. The method for producing a biopharmaceutical API according to any one of claims 1 to 12, wherein: The flow rate of the culture supernatant flowing into the sterile filter is constant.

14. The method for producing a biopharmaceutical API according to any one of claims 1 to 13, wherein: When the cumulative flow rate of the culture supernatant flowing into the sterile filter reaches 1000 L / m 2 ~10000L / m 2 Replace the sterile filter between set volumes.

15. The method for producing a biopharmaceutical API according to any one of claims 1 to 14, wherein: The flow rate of the culture supernatant flowing into the purification filter is varied by 50% or more at set intervals set between 2 minutes and 30 minutes.

16. The method for producing a biopharmaceutical API according to any one of claims 1 to 15, wherein: The culture supernatant is allowed to flow into a sampling container connected to the downstream of the sterile filter on the connection line.

17. The method for producing a biopharmaceutical API according to claim 16, wherein: The culture supernatant is caused to flow into the sampling container by a supply pump provided on a branch line connecting the connection line and the sampling container.

18. The method for producing a biopharmaceutical API according to any one of claims 1 to 17, wherein: The product is a protein.

19. The method for producing a biopharmaceutical API according to any one of claims 1 to 18, wherein: The cells are cells derived from Chinese hamster ovary cells.

20. A biopharmaceutical manufacturing system comprising: a culture section for performing a culture process of culturing cells in a culture solution stored in a culture tank and obtaining a culture supernatant containing a product of the cells by removing the cells from the culture solution using a cell removal filter; A purification section, which performs a purification process, wherein the purification process obtains a biopharmaceutical API by purifying the product from the culture supernatant, wherein the purification section is a purification process including a purification filter in a single-pass tangential flow filtration manner; connecting a pipeline to connect the culture section and the purification section; and A sterile filter is provided in the connecting line, the sterile filter has a larger pore size than the cell removal filter, and filters the culture supernatant flowing from the culture section into the purification section through the connecting line.

21. A biopharmaceutical API produced by the method for producing a biopharmaceutical API according to any one of claims 1 to 19.